%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Weiss, A.
%A Touret, F.
%A Baronti, Cécile
%A Gilles, Magali
%A Hoen, B.
%A Nougairede, A.
%A Lamballerie, X. de
%A Sommer, M. O. A.
%T Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
%D 2021
%L fdi:010083908
%G ENG
%J PLoS One
%@ 1932-6203
%M ISI:000735299000156
%N 12
%P e0260958 [8 ]
%R 10.1371/journal.pone.0260958
%U https://www.documentation.ird.fr/hor/fdi:010083908
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2022-02/010083908.pdf
%V 16
%W Horizon (IRD)
%X SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.
%$ 050 ; 052